Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients

Validated biomarkers predictive of response/resistance to anthracyclines in breast cancer are currently lacking. The neoadjuvant Trial of Principle (TOP) study, in which patients with estrogen receptor (ER)–negative tumors were treated with anthracycline (epirubicin) monotherapy, was specifically de...

Descripción completa

Detalles Bibliográficos
Autores principales: Haibe-Kains, B., Desmedt, C., Di Leo, A., Azambuja, E., Larsimont, D., Selleslags, J., Delaloge, S., Duhem, C., Kains, J.P., Carly, B., Maerevoet, M., Vindevoghel, A., Rouas, G., Lallemand, F., Durbecq, V., Cardoso, F., Salgado, R., Rovere, R., Bontempi, G., Michiels, S., Buyse, M., Nogaret, J.M., Qi, Y., Symmans, F., Pusztai, L., D'Hondt, V., Piccart-Gebhart, M., Sotiriou, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2013
Materias:
Data in Brief
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608867/
https://www.ncbi.nlm.nih.gov/pubmed/26484051
http://dx.doi.org/10.1016/j.gdata.2013.09.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608867/
https://www.ncbi.nlm.nih.gov/pubmed/26484051
http://dx.doi.org/10.1016/j.gdata.2013.09.001

Ejemplares similares